KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Enterprise Value (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Enterprise Value for 17 consecutive years, with -$8.3 billion as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 7.35% to -$8.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.3 billion through Dec 2025, down 7.35% year-over-year, with the annual reading at -$8.3 billion for FY2025, 7.35% down from the prior year.
  • Enterprise Value hit -$8.3 billion in Q4 2025 for Abbott Laboratories, down from -$7.4 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$6.4 billion in Q1 2024 to a low of -$10.0 billion in Q4 2021.
  • Historically, Enterprise Value has averaged -$8.1 billion across 5 years, with a median of -$7.9 billion in 2022.
  • Biggest five-year swings in Enterprise Value: plummeted 135.5% in 2021 and later surged 31.06% in 2024.
  • Year by year, Enterprise Value stood at -$10.0 billion in 2021, then rose by 0.76% to -$10.0 billion in 2022, then increased by 29.1% to -$7.1 billion in 2023, then dropped by 9.57% to -$7.7 billion in 2024, then fell by 7.35% to -$8.3 billion in 2025.
  • Business Quant data shows Enterprise Value for ABT at -$8.3 billion in Q4 2025, -$7.4 billion in Q3 2025, and -$7.0 billion in Q2 2025.